New drug duo tested for Tough-to-Treat cancer linked to HIV
NCT ID NCT02659930
Summary
This early-stage trial is testing the safety and initial effectiveness of combining two anti-cancer drugs, pomalidomide and liposomal doxorubicin, for people with advanced or hard-to-treat Kaposi sarcoma (KS). The study involves 62 adults with KS, including those with HIV, who receive the drugs in repeating monthly cycles. The main goals are to find the safest dose combination and see if the treatment helps shrink KS lesions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KAPOSI SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.